NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
出版年份 2022 全文链接
标题
NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
作者
关键词
-
出版物
Frontiers in Oncology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-03-17
DOI
10.3389/fonc.2022.864666
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
- (2021) Hayato Mizuta et al. Nature Communications
- Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib
- (2021) Shivaani Kummar et al. CURRENT PROBLEMS IN CANCER
- ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib
- (2021) Wenlong Li et al. MOLECULAR CANCER THERAPEUTICS
- A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report
- (2021) Lei Zhang et al. BMC Pulmonary Medicine
- Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications
- (2021) M.G. Krebs et al. ESMO Open
- Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer
- (2021) Zongliang Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
- (2021) Alvida Qvick et al. MOLECULAR MEDICINE
- Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
- (2021) C. B. Westphalen et al. npj Precision Oncology
- Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion
- (2021) Clare Keddy et al. Cold Spring Harbor Molecular Case Studies
- Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation
- (2021) Lin-Sheng Zhuo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Evaluating Targeted Next-Generation Sequencing Assays and Reference Materials for NTRK Fusion Detection
- (2021) Christina Bormann Chung et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations
- (2021) Brion W. Murray et al. MOLECULAR CANCER THERAPEUTICS
- ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability
- (2021) Wenlong Li et al. Pharmaceutics
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer
- (2020) Mi Ran Yun et al. CLINICAL CANCER RESEARCH
- Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry
- (2020) Wenlong Li et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein
- (2020) Holger Fischer et al. NEURO-ONCOLOGY
- Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification
- (2020) Dirk Hempel et al. ONCOLOGIST
- U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
- (2020) Kyriakos P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer
- (2020) Aria Vaishnavi et al. Cell Reports
- Larotrectinib followed by selitrectinib in a novel DCTN1–NTRK1 fusion undifferentiated pleomorphic sarcoma
- (2020) Xue Na Goh et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- FDA Approval Summary: Entrectinib for the treatment of NTRK-gene fusion solid tumors
- (2020) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
- (2020) Emiliano Cocco et al. Cancer Discovery
- Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer
- (2020) Xiaoyan Si et al. Thoracic Cancer
- Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
- (2020) Kenichi Suda et al. Translational Lung Cancer Research
- NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
- (2020) Romel Somwar et al. Communications Biology
- Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC
- (2020) Weihua Li et al. Journal of Thoracic Oncology
- Larotrectinib in adult patients with solid tumours: a multicentre, open-label, phase I dose-escalation study
- (2019) D S Hong et al. ANNALS OF ONCOLOGY
- Colorectal carcinomas containing hypermethylated MLH1 promoter and wild type BRAF/KRAS are enriched for targetable kinase fusions
- (2019) Emiliano Cocco et al. CANCER RESEARCH
- Durable clinical response to crizotinib in IRF2BP2-NRTK1 non-small cell lung cancer
- (2019) Buhai Wang et al. Clinical Lung Cancer
- Larotrectinib: First Global Approval
- (2019) Lesley J. Scott DRUGS
- Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS
- (2019) Jing Wang et al. MODERN PATHOLOGY
- High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden
- (2019) Ryma Benayed et al. CLINICAL CANCER RESEARCH
- Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry
- (2019) Rolf W. Sparidans et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Testing algorithm for identification of patients with TRK fusion cancer
- (2019) Frédérique Penault-Llorca et al. JOURNAL OF CLINICAL PATHOLOGY
- Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from TRK Inhibitor Therapy
- (2019) Susan J. Hsiao et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
- (2019) C Marchiò et al. ANNALS OF ONCOLOGY
- Entrectinib: First Global Approval
- (2019) Zaina T. Al-Salama et al. DRUGS
- Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
- (2019) Pengfei Zhao et al. Journal of Hematology & Oncology
- Evidence of NTRK1 fusions as resistance mechanism to EGFR TKI in EGFR+ NSCLC. Results from a large-scale survey of NTRK1 fusions in Chinese lung cancer patients
- (2019) Hui Xia et al. Clinical Lung Cancer
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
- (2019) James P. Solomon et al. MODERN PATHOLOGY
- Resistance to TRK inhibition mediated by convergent MAPK pathway activation
- (2019) Emiliano Cocco et al. NATURE MEDICINE
- Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
- (2019) E M O’Reilly et al. ANNALS OF ONCOLOGY
- Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
- (2019) A Amatu et al. ANNALS OF ONCOLOGY
- The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
- (2019) Ryohei Katayama et al. Nature Communications
- TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
- (2019) Ezra Y Rosen et al. CLINICAL CANCER RESEARCH
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors
- (2018) Erin R. Rudzinski et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Foretinib Overcomes Entrectinib Resistance Associated with theNTRK1G667C Mutation inNTRK1Fusion–Positive Tumor Cells in a Brain Metastasis Model
- (2018) Akihiro Nishiyama et al. CLINICAL CANCER RESEARCH
- Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics
- (2018) Yin P Hung et al. HISTOPATHOLOGY
- Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors
- (2018) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
- (2018) Theodore W Laetsch et al. LANCET ONCOLOGY
- The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
- (2018) Brandon Golding et al. Molecular Cancer
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study
- (2018) Yutaka Fujiwara et al. Oncotarget
- Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor
- (2018) Elena Helman et al. Clinical Lung Cancer
- Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
- (2018) Justin Taylor et al. JOURNAL OF CLINICAL INVESTIGATION
- Molecular characterization of cancers with NTRK gene fusions
- (2018) Zoran Gatalica et al. MODERN PATHOLOGY
- Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples
- (2018) Hannah L. Williams et al. VIRCHOWS ARCHIV
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
- (2018) Alexander Drilon et al. Cancer Discovery
- Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.
- (2018) Zofia Piotrowska et al. Cancer Discovery
- Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors
- (2018) Darren S. Sigal et al. Oncotarget
- Recent Advances in Targeting ROS1 in Lung Cancer
- (2017) Jessica J. Lin et al. Journal of Thoracic Oncology
- Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy
- (2017) Alanna J Church et al. MODERN PATHOLOGY
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
- (2017) Alison M. Schram et al. Nature Reviews Clinical Oncology
- A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
- (2017) Alexander Drilon et al. Cancer Discovery
- Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing
- (2017) Danielle A. Murphy et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Mammary Analogue Secretory Carcinoma of Salivary Glands
- (2016) Alena Skálová et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- What hides behind the MASC: clinical response and acquired resistance to entrectinib afterETV6-NTRK3identification in a mammary analogue secretory carcinoma (MASC)
- (2016) A. Drilon et al. ANNALS OF ONCOLOGY
- New and emerging targeted treatments in advanced non-small-cell lung cancer
- (2016) Fred R Hirsch et al. LANCET
- Secretory Breast Carcinoma
- (2015) Marie Del Castillo et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- ALK Testing in Lung Adenocarcinoma: Technical Aspects to Improve FISH Evaluation in Daily Practice
- (2015) Vittoria Martin et al. Journal of Thoracic Oncology
- Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
- (2015) Anna F. Farago et al. Journal of Thoracic Oncology
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
- (2015) R. C. Doebele et al. Cancer Discovery
- Anchored multiplex PCR for targeted next-generation sequencing
- (2014) Zongli Zheng et al. NATURE MEDICINE
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- TRKing Down an Old Oncogene in a New Era of Targeted Therapy
- (2014) Aria Vaishnavi et al. Cancer Discovery
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- (2013) Aria Vaishnavi et al. NATURE MEDICINE
- RETFusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
- (2012) Rui Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Mammary Analog Secretory Carcinoma of Salivary Gland Origin With the ETV6 Gene Rearrangement by FISH
- (2011) Ashton Connor et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Repetitive DNA and next-generation sequencing: computational challenges and solutions
- (2011) Todd J. Treangen et al. NATURE REVIEWS GENETICS
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More